Piper Sandler analyst Jessica Tassan lowered the firm’s price target on Doximity to $27 from $36 and keeps a Neutral rating on the shares. The company reduced fiscal 2024 revenue guidance citing mid-year upsells, net new business and renewal volume weakness, the analyst tells investors in a research note. The firm says these events challenge Doximity’s fiscal 2028 targets.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DOCS: